Cost efficiency of intranasal corticosteroid prescribing patterns in the management of allergic rhinitis.
BACKGROUND
Effective treatment of seasonal or perennial allergic rhinitis often requires use of topical intranasal corticosteroids (INSs). Despite differences in recommended starting dosages, the 4 leading INSs by market share are packaged in bottles containing 120 metered-dose sprays.


OBJECTIVE
To determine the relative prescribed dosages of the leading INSs and compare economic differences resulting from these prescribing behaviors.


METHODS
The IMS National Disease and Therapeutic Index (NDTI) was used to identify prescribing habits for the 4 leading INSs: fluticasone propionate nasal spray (FPNS), mometasone furoate aqueous nasal spray (MFNS), triamcinolone acetonide aqueous nasal spray (TANS), and budesonide aqueous nasal spray (BANS). The NDTI uses a national, randomly drawn, 2-stage stratified clustersampling methodology. Physicians are sampled during the first stage, with 2 workdays per month subsampled from each physician in the second stage. Each physician reports on all patient contacts during the 2 consecutive days, offering a continuing compilation of statistical information about patterns and treatment of disease encountered by office-based physicians. In a given month, the NDTI reports on 1180 unique physicians.


RESULTS
From January 1, 2002, to December 31, 2002, 58% of prescriptions for FPNS were for 4 sprays daily with 37% for 2 sprays daily, MFNS: 44% for 4 sprays and 52% for 2, TANS: 65% for 4 sprays and 31% for 2, and BANS: 29% for 4 sprays and 68% for 2. These equated to mean prescribed daily dosages of 3.47 sprays per day for FPNS, 3.33 for MFNS, 3.50 for TANS, and 2.73 for BANS. Because each INS is packaged in a bottle with 120 metered-dose sprays, the differences in dosage offer varying days of supply per unit filled. BANS offered the most days of treatment (44 days), followed by MFNS (38 days) and FPNS and TANS (means of 35 and 34 days, respectively) per single prescription filled. Cost per day of treatment was calculated by multiplying the prescribed dosage with the average wholesale price of the products. BANS had the lowest cost per day of treatment at US dollars 1.54, with each other INS costing at least an additional US dollars 0.26 daily (MFNS US dollars 1.80; FPNS US dollars 1.88; TANS US dollars 1.97).


CONCLUSIONS
Based on physician prescribing patterns of INSs from the NDTI database, BANS offers more days of treatment at a lower cost per day than other leading INSs.
Reissman
Debi
D
Rxperts, Irvine, CA 92618, USA.debi@rxperts.net
Price
Tom
T
Leibman
Christopher W
CW
D000281:Administration, Intranasal; D004363:Drug Utilization / Q000191:economics; D005938:Glucocorticoids / Q000008:administration & dosage / Q000191:economics*; D006801:Humans; D036501:Metered Dose Inhalers; D010818:Practice Patterns, Physicians' / Q000191:economics*; D012221:Rhinitis, Allergic, Perennial / Q000188:drug therapy / Q000191:economics*; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy / Q000191:economics*
D005938:Glucocorticoids